English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 19 November 2024, 17:37 HKT/SGT
Share:
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea
- Marking Another Milestone in Commercialization

HONG KONG, Nov 19, 2024 - (ACN Newswire) - Today, Everest Medicines announced that NEFECON(R) has received full approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.8 g/g). This approval further expands NEFECON(R)’s footprint in Asia and provides Asian patients with a groundbreaking etiological treatment option for IgAN.

Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, expressed his excitement about the approval: “As the world's first and only IgAN etiological treatment drug fully approved by the U.S. Food and Drug Administration (FDA), NEFECON(R) will provide a new treatment option for patients in South Korea. We will continue to work on enhancing the accessibility and affordability of NEFECON(R) across Asia to meet the urgent needs of more IgAN patients for this innovative therapy.”

NEFECON(R) is the first and only fully approved etiological treatment for IgAN, with its clinical value widely recognized by the global medical community. The approval of NEFECON(R) in South Korea is based on the global Phase 3 NefIgArd clinical trial, which showed that compared to placebo, NEFECON(R) not only brought about a sustained reduction in proteinuria and reduced the frequency of microscopic hematuria but also demonstrated clinically relevant and statistically significant treatment benefits in estimated glomerular filtration rate (eGFR). The study further revealed that NEFECON(R) reduces the decline in kidney function by 50%, over a period of 2 years, comprising 9 months of treatment and 15 months of observation, and potentially delay the progression to dialysis or kidney transplantation by 12.8 years.

Studies have shown that IgAN is highly prevalent among Asian populations, with a 56% higher risk of progression to end-stage renal disease compared to other groups, and often progresses more rapidly. The approval of NEFECON(R) in South Korea provides a breakthrough treatment option for IgAN patients in Asia and highlights its significant commercial potential in the region.

This milestone is further evidence of Everest Medicines’ robust global commercialization capabilities. Earlier this year, NEFECON(R) issued its first prescription in mainland China, with subsequent approvals in Macau, Hong Kong, Singapore (marketed as Nefegan(R)), and Taiwan China. According to the company’s interim report, NEFECON(R) achieved RMB 167.3 million in sales within just over a month of its commercial launch in China, demonstrating strong market performance. The approval in South Korea further validates NEFECON(R)’s clinical value and commercial potential, opening new market opportunities and creating an important revenue growth driver for the company.

Notably, NEFECON(R) participated in China’s National Reimbursement Drug List (NRDL) negotiations this year for the first time. Inclusion in the NRDL would significantly enhance its market penetration and affordability, accelerating its sales growth in China. Industry experts widely view NEFECON(R) as a potential blockbuster drug in the Chinese market, with the ability to drive Everest Medicines’ commercialization strategy while strengthening its competitive edge in both domestic and international markets.



Topic: Press release summary Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
HK Book Fair, Sports and Leisure Expo and World of Snacks open today  
July 18, 2025 08:25 HKT/SGT
IP Roundtable and International Publishing Forum held at Hong Kong Book Fair today  
July 18, 2025 08:24 HKT/SGT
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability  
July 18, 2025 00:05 HKT/SGT
Belgian Aircrew Completes MQ-9B Training  
July 18, 2025 00:05 HKT/SGT
A New Transatlantic Partnership for European CCA  
July 18, 2025 00:00 HKT/SGT
MHI-AP Awarded Long-term Service Contract for the Garabogazkarbamid Fertilizer Plant in Turkmenistan
  
Thursday, July 17, 2025 6:07:00 PM
Cornerstone Robotics Signs MOU with NHG Health and NTU Singapore to Facilitate Accessibility of RAS to Patients in Singapore  
July 17, 2025 17:45 HKT/SGT
Hong Kong Picture Book Publishing Support Programme Cultivates New Creative Forces, Eight Local Illustrators Shine on the International Stage  
July 17, 2025 16:51 HKT/SGT
Mitsubishi Motors Premieres the All-New Destinator in Indonesia  
Thursday, July 17, 2025 4:21:00 PM
Hitachi, global investment firm Brookfield, and global commodities trading firm Hartree Begin to Explore a Funding Scheme in the Environmentally-friendly Digital Infrastructure Sector  
Thursday, July 17, 2025 1:16:00 PM
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575